Onco Actu du 31 janvier 2017

	1. Biologie
Is there a reproducibility “crisis” in biomedical research? (2017 edition) [Respectful Insolence] We contacted Folkman, who provided reagents, protocols, and advice, as well as some angiostatin made in his laboratory. It turns out that the peptide we were making was easily denatured (unfolded), which was why it was not as potent as Folkman had reported. Now here’s why I say we couldn’t replicate his results.
	3.1 Tabac
£760 million annual bill from smoking ‘adding to social care crisis’ [Cancer Research UK] “Cutting the Public Health Grant is short-sighted if the Government is genuinely committed to reducing health inequalities, for which smoking is the leading cause.”
Smokers face tighter rules as Japanese capital eyes smoke-free Olympics [Reuters] Keisuke Kurimoto, a deputy director of the ministry's Health Services Section, said it was too early to say what the contents of the proposed bill will be or if it would be ready before the current session ends, probably in June.
	3.3 Prévention - Vaccins
HPV vaccine now funded for boys – Expert Q&A [Science Media Center] As students head back to school this week, boys, as well as girls, will have funded access to the HPV vaccine Gardasil. (New Zealand)
	4. Dépistage, diagnostic et pronostic
Breath test shows potential for detecting cancer [NHS Choices] These are early findings presented at a conference. While they show promise, it is not possible to say from the available information whether the test could have a future role in practice.
	4.10 Dép., diag. & prono. - Poumon
Lung Cancer Screening Program Finds A Lot That's Not Cancer [NPR] "Very few people are actually helped by screening, and a lot of time there are a number of harms."
	5. Traitements
Ovarian Chemo Shield? [Harvard Medical School] In their report receiving online publication in PNAS, a team from the Pediatric Surgical Research Laboratories in the Harvard-affiliated Massachusetts General Hospital (MGH) Department of Surgery describes using Mullerian Inhibiting Substance (MIS) to halt, in a mouse model, the early development of the ovarian follicles in which oocytes mature, an accomplishment that protects these primordial follicles from chemotherapy-induced damage.
Less-Frequent Zoledronic Acid Treatment Effective at Preventing Bone Metastasis Complications [NCI] In the trial—which was conducted through NCI’s Community Oncology Research Program—researchers at more than 250 academic and community treatment centers enrolled 1,822 patients with breast cancer, prostate cancer, or multiple myeloma and at least one bone metastasis.
	5.10 Traitements - Essais
Consider drug efficacy before first-in-human trials [Nature] “We must abandon the fiction that current oversight systems are adequate.”
	5.2 Pharma
Incyte grabs control of a cancer drug from Calithera’s pipeline for $53M up front [EndPoints] The collaboration gives Incyte the lead on CB-1158, a therapy designed to inhibit arginase, an enzyme that reins in T-cell and natural killer cell activation in tumors. The plan is to test it as a monotherapy but also in combination with immuno-oncology drugs – in particular an anti-PD-1 therapy – to test its potential for future combos.
	5.2.1 Pharma - Partenariats
Exelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan [Exelixis] Exelixis and Takeda will partner on cabozantinib’s clinical development in Japan and on translating existing and forthcoming clinical data for potential regulatory filings in the country.
	5.4 Traitements - Economie
1,100% generic cancer drug price increases fly below UK radar [Pharmafile] The reason that the current price increases have escaped notice until now is because the drugs that have been questioned are so old and without patent protection that it has been assumed that their prices would remain relatively low.
	6. Lutte contre les cancers
European experts highlight the potential of xenografts in personalized oncology [EurekAlert!] European research lays the foundation for the development of new and ambitious research projects with xenografts derived from patients, preclinical models with great potential to advance research and treatment in cancer.
	6.10.1 Politiques (USA)
MIT responds to Trump’s executive order on travel [MIT News] Leadership helps directly affected community members; President Reif speaks against the executive order and for national unity.
‘Two Out, One In’: Trump Signs Executive Order to Repeal Regulations [RAPS] According to the text of the EO, this plan will likely apply to FDA guidance documents too, which will be a problem for pharmaceutical and medical device companies that rely on such guidance to understand how FDA interprets the law.
Trump order on regulations could create hurdles for FDA, Cures Act [STAT] President Trump on Monday signed an executive order directing federal agencies to cut two regulations for every new one that they adopt, a move that could have significant implications for the Food and Drug Administration.
ASCO Statement on the U.S. Presidential Executive Order on Entry Into the United States [ASCO] We are reaching out to the ASCO members who are affected by the executive order and will do all we can to support their participation in ASCO’s scientific meetings and other educational opportunities that help advance patient care around the world.
	6.5 Médecines alternatives
“Detox”: Ritual purification masquerading as medicine and wellness [Science-Based Medicine] If the “central dogma” of alternative medicine is that wishing makes it so, one of the most important of the other organizing dogmas of alternative medicine is that “toxins,” whether they come from inside or outside, are making us sick and that we can’t be healthy until we “detoxify.” This is far more a religious belief than a science-based one.
	6.6 Publications
Study of child with rare cancer retracted due to lack of parental consent [Retraction Watch] In the June 2016 article, the authors stated they had received “written informed consent” from the parents to publish the case. But according to the retraction notice — issued just a few months later in October — that was not the case.
	6.7.3 DMP
Copy fees limit patient access to medical records, doctors argue [Reuters] Patients’ copy fees might reach as high as $218.70 for 150 pages of records in Minnesota, or $687.70 for 500 pages, researchers estimated.